Lipoprotein metabolism disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:29:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lipoprotein metabolism disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of LY3819469 for Adults with High Lipoprotein(a) Levels https://clinicaltrials.eu/trial/study-of-ly3819469-for-adults-with-high-lipoproteina-levels/ Wed, 29 Apr 2026 14:24:56 +0000 https://clinicaltrials.eu/trial/study-of-ly3819469-for-adults-with-high-lipoproteina-levels/ This clinical trial is focused on studying a condition known as elevated lipoprotein(a), which is a type of lipoprotein disorder. Lipoproteins are particles in the blood that carry cholesterol and other fats. When levels of lipoprotein(a) are high, it can increase the risk of heart disease. The study is testing a new treatment called LY3819469, which is a solution for injection developed by Eli Lilly and Company. This treatment is being compared to a placebo to see if it can effectively reduce the levels of lipoprotein(a) in the blood.

The purpose of the study is to determine if LY3819469 is better than a placebo in lowering lipoprotein(a) levels. Participants in the study will receive either the treatment or a placebo through an injection under the skin, known as a subcutaneous injection. The study will last for a period of time, during which participants will be monitored to see how their lipoprotein(a) levels change. The maximum daily dose of the treatment is 400 milligrams, and the total dose over the course of the study can be up to 800 milligrams.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to provide valuable information on the safety and effectiveness of LY3819469 for people with elevated lipoprotein(a) levels, potentially leading to new treatment options for this condition.

]]> Study of LY3473329 for Adults with High Lipoprotein(a) Levels at Risk for Heart Problems https://clinicaltrials.eu/trial/study-of-ly3473329-for-adults-with-high-lipoproteina-levels-at-risk-for-heart-problems/ Wed, 29 Apr 2026 14:24:51 +0000 https://clinicaltrials.eu/trial/study-of-ly3473329-for-adults-with-high-lipoproteina-levels-at-risk-for-heart-problems/ This clinical trial is focused on studying a condition known as elevated lipoprotein(a), which is a type of lipoprotein disorder. People with this condition have higher levels of a specific type of fat in their blood, which can increase the risk of heart-related problems. The study is testing a new treatment called LY3473329, which is a film-coated tablet taken by mouth. This medication is being developed by Eli Lilly and Company Limited and is a synthetic small molecule designed to help manage the levels of lipoprotein(a) in the blood.

The purpose of the study is to evaluate how effective and safe LY3473329 is for adults who have high levels of lipoprotein(a) and are at high risk for cardiovascular events, such as heart attacks or strokes. Participants in the study will be randomly assigned to receive either the medication or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of 12 weeks, during which participants will take the medication or placebo once daily.

Throughout the study, participants will be monitored to see how their lipoprotein(a) levels change from the beginning to the end of the 12-week period. The study aims to provide valuable information on whether LY3473329 can effectively lower lipoprotein(a) levels and reduce the risk of cardiovascular events in people with this condition. This research could lead to new treatment options for managing elevated lipoprotein(a) and improving heart health.

]]>